Lilly and JDRF partner on beta cell biomarker identification
The Juvenile Diabetes Research Foundation and US drug major Eli Lilly are joining together to create a $3.0-million research effort to accelerate the pace of research into drugs and therapies to cure diabetes and its complications by developing biomarkers - indicators that can measure the progress of disease and the effectiveness of therapeutics.
The project - dubbed the JDRF-Lilly Innovative and Academic Research and Development Grants in Diabetes Biomarkers - will be funded by a $3.0 million grant from the Lilly Foundation to the JDRF over three years.
The JDRF is one of the world's largest charitable funder of type 1 diabetes research; over the last year, it has given more than $137.0 million to research for cures and develop therapeutics for type 1 diabetes and its complications, says Lilly, a global leader in diabetes science and treatment, dating back to the development of the world's first commercially-available insulin in the 1920s.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze